iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Benchmarks trade with losses; PSU banks outperform

18 Nov 2022 , 10:25 AM

The key equity benchmarks tumbled and traded with limited losses in morning trade. The Nifty traded below the 18,300 level. PSU Banks, however, extended their bull run for fourth consecutive session. At 10:22 IST, the barometer index, the S&P BSE Sensex, was down 160.67 points or 0.26% to 61,589.93. The Nifty 50 index lost 53.15 points or 0.29% to 18,290.75. In the broader market, the S&P BSE Mid-Cap index declined 0.40% while the S&P BSE Small-Cap index slipped 0.14%. Nazara Technologies (up 8.03%), IFB Industries (up 7.97%), IIFL Finance (up 5.31%), PB Fintech (up 4.94%) and AIA Engineering (up 4.46%) were the top broader market gainers. Mazagon Dock Shipbuilders (down 5.14%), Manappuram Finance (down 4.56%), HUDCO (down 4.19%), Shoppers Stop (down 4.03%) and Campus Activewear (down 3.02%) were the top losers in the broader market segment. The market breadth was positive. On the BSE, 1,529 shares rose and 1,571 shares fell. A total of 153 shares were unchanged. Buzzing Index: The Nifty PSU Bank index rose 1.60% to 3,852. The index has added 3.04% in four sessions. Bank of Maharashtra (up 8.23%), Punjab National Bank (up 4.29%), Indian Overseas Bank (up 4.2%), Central Bank of India (up 4.16%) and Punjab & Sind Bank (up 3.84%) were the top gainers. Among the other gainers were Bank of India (up 3.7%), UCO Bank (up 3.65%), Union Bank of India (up 3.63%), Canara Bank (up 0.83%) and State Bank of India (up 0.63%). Stocks in Spotlight: Blue Dart rose 1.40%. The company announced the opening of 25 retail outlets in Tier I and II towns as part of its expansion plans. These stores are located in Uttarakhand, Haryana, Uttar Pradesh, Rajasthan, Punjab, West Bengal, Odisha, Telangana, Andhra Pradesh, Kerala, Karnataka, Maharashtra, Goa and Gujarat. Aurobindo Pharma shed 0.41%. The companys wholly owned subsidiary company, Eugia Pharma Specialities has received a final approval from the US Food & Drug Administration (US FDA) for hotericin B Liposome for injection. The product is expected to be launched by Q4 FY23. The approved product has an estimated market size of around US$ 145 million for the twelve months ending September 2022, according to IQVIA. Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.